Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388274 | 0.87 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18295025 | 0.81 | MAPT (0.47) | KMT2AMEN1ALDH1A1HTTKDM4E | |
| SCHEMBL16344890 | 0.78 | MEN1 (0.49) | KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL17546494 | 0.78 | LMNA (0.66) | KMT2AMEN1HDAC3HDAC4HDAC1 | |
| SCHEMBL14163900 | 0.75 | AURKA (0.40) | ALDH1A1HTTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL19114231 | 0.75 | BRD4 (0.36) | ALDH1A1HTTKDM4ERAB9AGAA | |
| SCHEMBL24159640 | 0.74 | LMNA (0.57) | KMT2AALDH1A1HTTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29002976 | 0.74 | AURKA (0.39) | ALDH1A1HTTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL14638663 | 0.73 | KMT2A (0.49) | KMT2AMEN1HDAC3HDAC4HDAC1 | |
| SCHEMBL3098637 | 0.73 | KMT2A (0.49) | KMT2AMEN1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-2734505-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-05-28 | — | — | EP | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2148877-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | VHL, HIF1AN, HIF1A | KMT2A 2770/4885MEN1 1673/4885HDAC3 377/4885 |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | FLT4, VEGFA, MKI67 | KMT2A 3476/4885MEN1 3176/4885HDAC3 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.